The initial recall was announced in late December, but the FDA has now classified it as a Class I recall, indicating a reasonable probability that exposure could lead to serious adverse health consequences or even death. This warning specifically targets those with milk allergies, urging affected consumers to assess their pantry for potential risks.
Packaged on or before November 3, 2024, the impacted bags feature “guaranteed fresh” dates of February 11, 2025, alongside manufacturing codes 6462307xx or 6463307xx. Thankfully, no other Lay’s products are involved in this recall, and the FDA has reported no allergic reactions tied to the chips thus far.
It is essential for consumers in Oregon and Washington to take heed of this recall to prevent any health complications. For now, the broader public remains unaffected, but vigilance is advised for those who may have purchased these specific products.
Additionally, while the FDA has not clarified the reasons behind its severe classification of this incident, it is notable that public health communications have faced interruptions following policy changes in the federal government. As the situation evolves, further updates may be provided by the agency as the FDA resumes its regular communications.
Packaged on or before November 3, 2024, the impacted bags feature “guaranteed fresh” dates of February 11, 2025, alongside manufacturing codes 6462307xx or 6463307xx. Thankfully, no other Lay’s products are involved in this recall, and the FDA has reported no allergic reactions tied to the chips thus far.
It is essential for consumers in Oregon and Washington to take heed of this recall to prevent any health complications. For now, the broader public remains unaffected, but vigilance is advised for those who may have purchased these specific products.
Additionally, while the FDA has not clarified the reasons behind its severe classification of this incident, it is notable that public health communications have faced interruptions following policy changes in the federal government. As the situation evolves, further updates may be provided by the agency as the FDA resumes its regular communications.
